Glucose control during 3-month treatment with bihormonal artificial pancreas versus current diabetes care in patients after total pancreatectomy: study protocol for the PANORAMA randomized crossover trial
Patients undergoing total pancreatectomy (TP) will develop insulin-dependent diabetes, which is challenging to manage due to the complete absence of insulin and glucagon1. In recent years, the first European Commission-marked bihormonal artificial pancreas (BIHAP; Inreda Diabetic, Goor, the Netherla...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
February 2026
|
| In: |
BJS open
Year: 2026, Volume: 10, Pages: 1-2 |
| ISSN: | 2474-9842 |
| DOI: | 10.1093/bjsopen/zraf151 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/bjsopen/zraf151 |
| Author Notes: | Charlotte A Leseman, Charlotte L van Veldhuisen, Ingmar F Rompen, Stefan A Bouwense, Koop Bosscha, Olivier R Busch, Marcel GW Dijkgraaf, Casper HJ van Eijck, Job S de Haan, Roel Haen, Ignace HJ de Hingh, V de Meijer, Maarten W Nijkamp, J Sven D Mieog, I Quintus Molenaar, Hjalmar C van Santvoort, Martijn WJ Stommel, Rogier P Voermans, Johanna W Wilmink, J Hans De Vries and Marc G Besselink, on behalf of the Dutch Pancreatic Cancer Group |
| Summary: | Patients undergoing total pancreatectomy (TP) will develop insulin-dependent diabetes, which is challenging to manage due to the complete absence of insulin and glucagon1. In recent years, the first European Commission-marked bihormonal artificial pancreas (BIHAP; Inreda Diabetic, Goor, the Netherlands) was introduced as a novel approach for the treatment of type 1 diabetes, with encouraging results2. Recently, the BIHAP was tested for the first time in patients after TP3. In a pilot study3, diabetes treatment with the BIHAP versus current diabetes treatment was compared in 10 patients after TP over a period of 7 days. This randomized crossover clinical trial demonstrated that the BIHAP can provide superior glucose control compared with current diabetes care (median time spent in range 78% (interquartile range (i.q.r.) 71-83%) versus 57% (i.q.r. 52-81%), respectively; P = 0.03). |
|---|---|
| Item Description: | Online veröffentlicht: 20. Januar 2026 Gesehen am 25.03.2026 |
| Physical Description: | Online Resource |
| ISSN: | 2474-9842 |
| DOI: | 10.1093/bjsopen/zraf151 |